Arterial Thrombosis-Pipeline Review, H1 2016

Arterial Thrombosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7739IDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Arterial Thrombosis-Pipeline Review, H1 2016', provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis

The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects

The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Arterial Thrombosis Overview 7

Therapeutics Development 8

Pipeline Products for Arterial Thrombosis-Overview 8

Pipeline Products for Arterial Thrombosis-Comparative Analysis 9

Arterial Thrombosis-Therapeutics under Development by Companies 10

Arterial Thrombosis-Therapeutics under Investigation by Universities/Institutes 11

Arterial Thrombosis-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Arterial Thrombosis-Products under Development by Companies 15

Arterial Thrombosis-Products under Investigation by Universities/Institutes 16

Arterial Thrombosis-Companies Involved in Therapeutics Development 17

Astellas Pharma Inc. 17

AstraZeneca Plc 18

Bayer AG 19

Bristol-Myers Squibb Company 20

Eisai Co., Ltd. 21

Johnson & Johnson 22

Sanofi 23

Arterial Thrombosis-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AS-1468240-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ASP-1645-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ASP-6537-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

BAY-1213790-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

BMS-593214-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

BMS-654457-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

C-3-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

E-5539-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ER-410660-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

JNJ-375-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

PZ-128-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

SAR-216471-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

ticagrelor-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Arterial Thrombosis-Recent Pipeline Updates 51

Arterial Thrombosis-Dormant Projects 57

Arterial Thrombosis-Product Development Milestones 58

Featured News & Press Releases 58

Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Figures

Number of Products under Development for Arterial Thrombosis, H1 2016 8

Number of Products under Development for Arterial Thrombosis-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Targets, H1 2016 25

Number of Products by Stage and Targets, H1 2016 25

Number of Products by Mechanism of Actions, H1 2016 27

Number of Products by Stage and Mechanism of Actions, H1 2016 27

Number of Products by Routes of Administration, H1 2016 29

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Arterial Thrombosis, H1 2016 8

Number of Products under Development for Arterial Thrombosis-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Investigation by Universities/Institutes, H1 2016 16

Arterial Thrombosis-Pipeline by Astellas Pharma Inc., H1 2016 17

Arterial Thrombosis-Pipeline by AstraZeneca Plc, H1 2016 18

Arterial Thrombosis-Pipeline by Bayer AG, H1 2016 19

Arterial Thrombosis-Pipeline by Bristol-Myers Squibb Company, H1 2016 20

Arterial Thrombosis-Pipeline by Eisai Co., Ltd., H1 2016 21

Arterial Thrombosis-Pipeline by Johnson & Johnson, H1 2016 22

Arterial Thrombosis-Pipeline by Sanofi, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Arterial Thrombosis Therapeutics-Recent Pipeline Updates, H1 2016 51

Arterial Thrombosis-Dormant Projects, H1 2016 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Astellas Pharma Inc. AstraZeneca Plc Bayer AG Bristol-Myers Squibb Company Eisai Co., Ltd. Johnson & Johnson Sanofi

Arterial Thrombosis Therapeutic Products under Development, Key Players in Arterial Thrombosis Therapeutics, Arterial Thrombosis Pipeline Overview, Arterial Thrombosis Pipeline, Arterial Thrombosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com